Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$3.96
-8.5%
$6.79
$3.93
▼
$31.35
$512.54M-0.282.21 million shs1.79 million shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$6.91
-6.0%
$9.77
$6.75
▼
$13.90
$634.89M0.561.75 million shs1.75 million shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$1.96
-1.0%
$3.16
$1.32
▼
$5.08
$125.26M1.33954,447 shs1.52 million shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$11.04
+0.1%
$11.64
$9.46
▼
$23.29
$939.61M1.141.53 million shs1.69 million shs
7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
-1.37%-29.36%-35.37%-82.09%-34.09%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+0.14%-1.08%-26.35%-38.18%-35.07%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
+0.51%-13.54%-43.27%-51.71%+39.44%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
+2.22%-14.30%+6.88%-30.01%-18.54%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$3.96
-8.5%
$6.79
$3.93
▼
$31.35
$512.54M-0.282.21 million shs1.79 million shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$6.91
-6.0%
$9.77
$6.75
▼
$13.90
$634.89M0.561.75 million shs1.75 million shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$1.96
-1.0%
$3.16
$1.32
▼
$5.08
$125.26M1.33954,447 shs1.52 million shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$11.04
+0.1%
$11.64
$9.46
▼
$23.29
$939.61M1.141.53 million shs1.69 million shs
7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
-1.37%-29.36%-35.37%-82.09%-34.09%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+0.14%-1.08%-26.35%-38.18%-35.07%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
+0.51%-13.54%-43.27%-51.71%+39.44%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
+2.22%-14.30%+6.88%-30.01%-18.54%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alumis Inc. stock logo
ALMS
Alumis
2.86
Moderate Buy$31.27689.72% Upside
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.77
Moderate Buy$25.88274.56% Upside
MacroGenics, Inc. stock logo
MGNX
MacroGenics
2.40
Hold$8.50333.67% Upside
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
2.60
Moderate Buy$31.33183.82% Upside

Current Analyst Ratings Breakdown

Latest MGNX, KURA, MLTX, and ALMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
DowngradeSell (D-) ➝ Sell (E+)
11/16/2026
Alumis Inc. stock logo
ALMS
Alumis
Lower Price TargetOutperform$28.00
11/13/2026
Alumis Inc. stock logo
ALMS
Alumis
UpgradeSell (E+) ➝ Sell (D-)
11/13/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
DowngradeSell (D-) ➝ Sell (E+)
11/13/2026
Alumis Inc. stock logo
ALMS
Alumis
Lower Price TargetOverweight$25.00 ➝ $18.00
11/13/2026
Alumis Inc. stock logo
ALMS
Alumis
Lower Price TargetBuy$15.00 ➝ $9.00
11/12/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Set Price TargetOutperform$34.00
11/12/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Reiterated RatingMarket Outperform
11/12/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Set Price Target$24.00
11/6/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Initiated CoverageBuy$57.00
11/3/2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
Reiterated RatingSell (D-)
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alumis Inc. stock logo
ALMS
Alumis
$24.05M21.31N/AN/A$2.92 per share1.36
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$67.48M9.41N/AN/A$0.20 per share34.55
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$149.50M0.84N/AN/A$0.39 per share5.03
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$4.48 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alumis Inc. stock logo
ALMS
Alumis
-$243.32M-$3.53N/AN/AN/A-5,844.54%-89.77%-71.50%N/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$278.67M-$3.30N/AN/AN/A-369.26%-336.24%-46.03%N/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$74.62M-$0.81N/AN/AN/A-45.37%-246.62%-31.36%N/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$227.32M-$3.67N/AN/AN/AN/A-79.95%-56.40%N/A

Latest MGNX, KURA, MLTX, and ALMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Alumis Inc. stock logo
ALMS
Alumis
-$0.7580-$0.73+$0.0280-$0.73$1.90 million$1.91 million
11/10/2026Q3 2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.8197-$0.78+$0.0397-$0.78$24.94 million$22.84 million
11/4/2026Q3 2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.8326-$0.93-$0.0974-$0.93N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alumis Inc. stock logo
ALMS
Alumis
N/A
5.57
5.57
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.07
3.60
3.56
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/A
2.75
2.75
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.26
9.13
9.13

Institutional Ownership

CompanyInstitutional Ownership
Alumis Inc. stock logo
ALMS
Alumis
N/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
96.89%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
93.85%

Insider Ownership

CompanyInsider Ownership
Alumis Inc. stock logo
ALMS
Alumis
33.70%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
7.60%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
13.60%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alumis Inc. stock logo
ALMS
Alumis
239129.43 million85.82 millionOptionable
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
26091.88 million84.90 millionOptionable
MacroGenics, Inc. stock logo
MGNX
MacroGenics
29363.91 million55.22 millionOptionable
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
13085.11 million76.26 millionOptionable

Recent News About These Companies

What is HC Wainwright's Estimate for MLTX FY2026 Earnings?
How Moonlake Immunotherapeutics (MLTX) Affects Rotational Strategy Timing
MoonLake Immunotherapeutics (MLTX) Gets a Buy from Guggenheim

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alumis stock logo

Alumis NASDAQ:ALMS

$3.96 -0.37 (-8.55%)
Closing price 04:00 PM Eastern
Extended Trading
$4.01 +0.05 (+1.39%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Kura Oncology stock logo

Kura Oncology NASDAQ:KURA

$6.91 -0.44 (-5.99%)
Closing price 04:00 PM Eastern
Extended Trading
$6.90 0.00 (-0.07%)
As of 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

MacroGenics stock logo

MacroGenics NASDAQ:MGNX

$1.96 -0.02 (-1.01%)
Closing price 04:00 PM Eastern
Extended Trading
$1.96 +0.01 (+0.26%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$11.04 +0.01 (+0.09%)
Closing price 03:58 PM Eastern
Extended Trading
$11.08 +0.04 (+0.32%)
As of 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.